Related references
Note: Only part of the references are listed.Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals
Ling Wang et al.
AIDS (2016)
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Michal Baniyash
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Role of the tumor stroma in resistance to anti-angiogenic therapy
Elisabeth J. M. Huijbers et al.
DRUG RESISTANCE UPDATES (2016)
Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S
Hirotake Abe et al.
HUMAN CELL (2016)
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients
Sarah Cattin et al.
ONCOTARGET (2016)
Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
Hee Jin Lee et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Inflammatory breast cancer: An overview
D. J. P. van Uden et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shabnam Shalapour et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Douglas Marvel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Intertwined regulation of angiogenesis and immunity by myeloid cells
Lee B. Rivera et al.
TRENDS IN IMMUNOLOGY (2015)
Mechanism of tumour vascularization in experimental lung metastases
Vanessza Szabo et al.
JOURNAL OF PATHOLOGY (2015)
Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity
Yan Shi et al.
FEBS JOURNAL (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
Inflammatory and microenvironmental factors involved in breast cancer progression
Mina Ham et al.
ARCHIVES OF PHARMACAL RESEARCH (2013)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
Srinivas Nagaraj et al.
JOURNAL OF IMMUNOLOGY (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
Tom Donnem et al.
CANCER MEDICINE (2013)
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
Magali Terme et al.
ONCOIMMUNOLOGY (2013)
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model
Keunhee Oh et al.
BREAST CANCER RESEARCH (2013)
Contrasting effects of sunitinib within in vivo models of metastasis
Jonathan C. Welti et al.
ANGIOGENESIS (2012)
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan et al.
CANCER CELL (2012)
Modulation of Immunity by Antiangiogenic Molecules in Cancer
Magali Terme et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Stromal biomarkers in breast cancer development and progression
Jenny A. Rudnick et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy
Francois Kuonen et al.
CLINICAL CANCER RESEARCH (2012)
Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kendra D. Simpson et al.
JOURNAL OF IMMUNOLOGY (2012)
Anti-angiogenic Therapy: Concept to Clinic
Robin J. Young et al.
MICROCIRCULATION (2012)
Anti-VEGF Therapies in the Clinic
Kellen L. Meadows et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction
Sabrina Danilin et al.
ONCOIMMUNOLOGY (2012)
Role of Bone Marrow-Derived Cells in Angiogenesis: Focus on Macrophages and Pericytes
Yanping Ding et al.
CANCER MICROENVIRONMENT (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Eric Tartour et al.
CANCER AND METASTASIS REVIEWS (2011)
Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer during Differentiation of Their Hematopoietic Progenitors
Julien Laurent et al.
CANCER RESEARCH (2011)
Basic and Therapeutic Aspects of Angiogenesis
Michael Potente et al.
CELL (2011)
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
James Finke et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells
Julien Laurent et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
Tumor angiogenesis: molecular pathways and therapeutic targets
Sara M. Weis et al.
NATURE MEDICINE (2011)
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Presence of Tumor-infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma Are Prognostic Factors for Relapse-Free Survival of Patients With Thick (T4) Primary Melanoma
Uma N. M. Rao et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Myeloid-Derived Suppressor Cells in Human Cancer
Srinivas Nagaraj et al.
CANCER JOURNAL (2010)
Myeloid-derived suppressor cell heterogeneity and subset definition
Elisa Peranzoni et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Ilaria Marigo et al.
IMMUNITY (2010)
Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis
Xian-Zong Ye et al.
JOURNAL OF GENETICS AND GENOMICS (2010)
Bevacizumab for advanced breast cancer
Shari B. Goldfarb et al.
WOMENS HEALTH (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Myeloid-Derived Suppressor Cells: A Novel Therapeutic Target
Jennifer S. Ko et al.
CURRENT ONCOLOGY REPORTS (2009)
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells
Paolo Serafini et al.
CANCER RESEARCH (2008)
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Girieca Lorusso et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Analyzing real-time PCR data by the comparative C-T method
Thomas D. Schmittgen et al.
NATURE PROTOCOLS (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy
James E. Talmadge
CLINICAL CANCER RESEARCH (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
Pratima Sinha et al.
CANCER RESEARCH (2007)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
M Franco et al.
CANCER RESEARCH (2006)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Endothelial cell integrins and COX-2:: mediators and therapeutic targets of tumor angiogenesis
C Rüegg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2004)
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
PC Rodriguez et al.
CANCER RESEARCH (2004)
VEGF as a Mediator of tumor-associated immunodeficiency
JE Ohm et al.
IMMUNOLOGIC RESEARCH (2001)
Share Paper
